Tau (phospho T212) Recombinant Rabbit mAb (SDT-3696-102)

Phosphorylated Tau at threonine 212 (p-Tau212) is a core pathological biomarker derived from abnormal hyperphosphorylation of tau protein, which directly participates in neurofibrillary tangle formation, a hallmark pathological lesion of Alzheimer’s disease (AD). Under physiological conditions, tau protein maintains microtubule stability in neurons. Once abnormally phosphorylated at Thr212, tau dissociates from cytoskeleton, aggregates into insoluble fibrils, and triggers neuronal damage, synaptic dysfunction and progressive neurodegeneration.

As a peripheral and cerebrospinal fluid (CSF) biomarker, p-Tau212 exhibits prominent diagnostic performance in AD screening and differential diagnosis. It shows strong specificity for early AD pathological changes, and can detect tauopathy at preclinical and mild cognitive impairment (MCI) stages prior to obvious clinical dementia symptoms. Compared with conventional p-Tau biomarkers including p-Tau181 and p-Tau217, p-Tau212 displays distinctive superiority in distinguishing AD from other neurodegenerative diseases such as frontotemporal dementia, vascular dementia and Parkinson’s disease.

Serum p-Tau212 achieves favorable diagnostic efficacy with high sensitivity and specificity in non-invasive detection. Its level is closely correlated with disease severity, cognitive decline degree and cerebral tau pathological burden. Dynamic changes of p-Tau212 also provide reliable evidence for disease progression monitoring, therapeutic effect evaluation and prognostic assessment.

Nevertheless, single p-Tau212 detection still has partial limitations. Combined detection with Aβ and other tau phosphorylated epitopes is recommended to improve overall diagnostic accuracy. In conclusion, p-Tau212 is a valuable early diagnostic biomarker for AD, with great translational potential in clinical IVD detection and longitudinal follow-up.